Opportunities often unfurl in the most unexpected of places, especially within the murky waters of oversold health care stocks. This sector is a treasure trove of undervalued gems awaiting the keen eye of investors seeking ripe prospects.
One such barometer of a stock’s momentum is the Relative Strength Index (RSI), a gauge that juxtaposes a stock’s strength on bullish versus bearish market days. When RSI plunges below 30, it indicates that a stock may be oversold, heralding a potential upswing in the near term.
Let’s delve into the realm of oversold health care stocks with RSI values hovering near or below 30.
The Resilient Haemonetics Corporation (NYSE: HAE)
- Recently, on August 8, Haemonetics defied odds by unveiling quarterly earnings that surpassed expectations. Despite this feat, the company’s stock plummeted by approximately 19% in the past month, hitting a 52-week low of $70.74.
- RSI Value: 25.47
- HAE Price Action: Haemonetics’ shares staged a modest recovery, edging up by 1.1% to settle at $73.99 on Thursday.
ImmunityBio Inc’s Steady Ascent (NASDAQ: IBRX)
- On August 6, ImmunityBio sparked optimism with the announcement of a study involving ANKTIVA in tandem with the AdHER2DC cancer vaccine to combat endometrial cancer. Despite a recent nosedive of about 38% in its stock value over the past month, ImmunityBio stood tall with a 52-week low of $1.25.
- RSI Value: 29.87
- IBRX Price Action: ImmunityBio’s shares exhibited a resilient climb, gaining 2.6% to conclude at $3.98 on Thursday.
Progyny Inc: Weathering the Storm (NASDAQ: PGNY)
- Amidst the market whirlwinds, Progyny faced headwinds with second-quarter revenue results falling short of expectations. Despite this setback, the company’s utilization rates remained steady, providing a glimmer of hope. Progyny’s shares weathered a stormy decline of around 31% in the past month, hitting a 52-week low of $19.60.
- RSI Value: 29.06
- PGNY Price Action: Progyny’s resilience shone through as its shares edged up by 1.7% to close at $20.85 on Thursday.
Explore the Possibilities:
